Coleman K Obasaju
Overview
Explore the profile of Coleman K Obasaju including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
1105
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Patel J, Paz-Ares L, Zinner R, Barlesi F, Koustenis A, Obasaju C
Clin Lung Cancer
. 2018 Oct;
19(6):e823-e830.
PMID: 30369427
Although lung cancer prognosis remains poor for most patients, treatments developed in the past 2 decades have extended survival for many. For those with disease that responded to or those...
2.
Chen L, Brown J, Marmaduke D, Mayo C, Grau G, Lau Y, et al.
Support Care Cancer
. 2018 Feb;
26(7):2369-2377.
PMID: 29423677
Purpose: Rash toxicity is a common, expected class effect of epidermal growth factor receptor (EGFR) inhibitors. Although rash management is practiced, it is not well characterized in the real-world setting....
3.
Soulieres D, Aguilar J, Chen E, Misiukiewicz K, Ernst S, Lee H, et al.
BMC Cancer
. 2016 Jan;
16:19.
PMID: 26768732
Background: Cetuximab, in combination with platinum chemotherapy plus 5-fluoruracil (5-FU), is approved for the first-line treatment of recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN). Cetuximab manufactured by...
4.
Reynolds C, Patel J, Garon E, Olsen M, Bonomi P, Govindan R, et al.
Clin Lung Cancer
. 2014 Dec;
16(3):200-8.
PMID: 25516338
Introduction: African Americans have a greater incidence of lung cancer than whites and have been underrepresented in clinical trials. In the PointBreak trial (pemetrexed-carboplatin-bevacizumab and maintenance pemetrexed-bevacizumab [PemCBev] vs. paclitaxel-carboplatin-bevacizumab...
5.
Zinner R, Obasaju C, Spigel D, Weaver R, Beck J, Waterhouse D, et al.
J Thorac Oncol
. 2014 Nov;
10(1):134-42.
PMID: 25371077
Introduction: PRONOUNCE compared the efficacy and safety of pemetrexed+carboplatin followed by pemetrexed (Pem+Cb) with paclitaxel+carboplatin+bevacizumab followed by bevacizumab (Pac+Cb+Bev) in patients with advanced nonsquamous non-small-cell lung cancer (NSCLC). Methods: Patients...
6.
Patel J, Socinski M, Garon E, Reynolds C, Spigel D, Olsen M, et al.
J Clin Oncol
. 2013 Oct;
31(34):4349-57.
PMID: 24145346
Purpose: PointBreak (A Study of Pemetrexed, Carboplatin and Bevacizumab in Patients With Nonsquamous Non-Small Cell Lung Cancer) compared the efficacy and safety of pemetrexed (Pem) plus carboplatin (C) plus bevacizumab...
7.
Pennella E, Obasaju C, Pohl G, Peltz G, Girvan A, Winfree K, et al.
Clin Lung Cancer
. 2013 Aug;
14(6):726-35.
PMID: 23910068
Introduction: This prospective observational study evaluated the effect of race on disease control rate (DCR), progression-free survival (PFS), and overall survival (OS) in patients with NSCLC treated with second-line pemetrexed....
8.
Argiris A, Pennella E, Koustenis A, Hossain A, Obasaju C
Oral Oncol
. 2013 Mar;
49(6):492-501.
PMID: 23466170
Pemetrexed has been evaluated as a novel chemotherapeutic for head and neck cancer (HNC). In this review, we examined the efficacy and tolerability of pemetrexed in patients with HNC. Relevant...
9.
Treat J, Scagliotti G, Peng G, Monberg M, Obasaju C, Socinski M
Lung Cancer
. 2011 Nov;
76(2):222-7.
PMID: 22115704
Introduction: In a first-line study of advanced NSCLC, pemetrexed-cisplatin was more effective among patients with adenocarcinoma and large-cell carcinoma compared with gemcitabine-cisplatin (median survival of 11.8 versus 10.4 months, P=.005),...
10.
Gordon A, Teneriello M, Janicek M, Hines J, Lim P, Chen M, et al.
Gynecol Oncol
. 2011 Oct;
123(3):479-85.
PMID: 21978765
Objective: The safety and efficacy of gemcitabine plus carboplatin (GC) or paclitaxel plus carboplatin (TC) induction regimens with or without paclitaxel consolidation therapy were assessed in ovarian cancer (OC). Methods:...